关键词: 结直肠癌, 靶向治疗, 耐药, 表皮生长因子受体, 血管内皮生长因子受体

Abstract: The drug resistance of colorectal cancer is closely related to individual differences and the heterogeneity of tumor cells, among which the different mutation loads of drug resistance-related genes largely determine the therapeutic effect of tumor-targeted drugs. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are currently the clearest targets with the most diverse related drugs in the targeted therapy of colorectal cancer. In the past few decades, the adjuvant treatment methods for colorectal cancer have been constantly evolving. However, in clinical practice, there are difficulties in developing new drugs for many targets with well-proven drug resistance, and a wider range of molecular markers are needed to evaluate the adaptability and efficacy of targeted therapy. The highly sensitive genome sequencing methods and continuously improving molecular detection methods have brought great convenience to explore the drug resistance mechanism of colorectal cancer and evaluate the expression of personalized molecules. By continuously deepening the understanding of the drug resistance mechanism of colorectal cancer, it is expected to explore more targeted treatment loci for colorectal cancer and provide personalized adjunctive treatment plans for patients by individually evaluating the molecular expression characteristics of different patients, improving the prognosis of advanced colorectal cancer patients.

Key words: colorectal cancer, targeted therapy, drug resistance, epidermal growth factor receptor, vascular endothelial growth factor receptor